Status:
COMPLETED
A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections
Lead Sponsor:
Pfizer
Conditions:
Invasive Fungal Infections
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
To evaluate the efficacy and safety of voriconazole in Chinese patients with proven or probable deep tissue fungal infections.
Eligibility Criteria
Inclusion
- Subjects with proven or probable invasive fungal infections including subjects who have failed to respond to, or have an intolerance to other approved antifungal treatments and with approval for salvage treatment by Principal Investigator and Pfizer.
Exclusion
- Subjects who are showing continuing improvement with other antifungal agents, including amphotericin B, itraconazole, nystatin, fluconazole, flucytosine and miconazole.
- Subjects with an invasive fungal infection caused by a fungus (such as Mucor) that is not in the antifungal spectrum of voriconazole.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00288197
Start Date
January 1 2006
End Date
June 1 2007
Last Update
June 12 2008
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Guangzhou, Guangdong, China, 510080
2
Pfizer Investigational Site
Wuhan, Hubei, China, 430022
3
Pfizer Investigational Site
Wuhan, Hubei, China, 430030
4
Pfizer Investigational Site
Beijing, China, 100083